Compare CTNT & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTNT | APVO |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 5.1M |
| IPO Year | 2023 | 2023 |
| Metric | CTNT | APVO |
|---|---|---|
| Price | $1.81 | $3.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 364.6K | 31.0K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.74 | 0.13 |
| EPS | ★ N/A | N/A |
| Revenue | $1,288,536.00 | ★ $3,114,000.00 |
| Revenue This Year | $42.49 | N/A |
| Revenue Next Year | $22.22 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 182.69 | N/A |
| 52 Week Low | $0.02 | $0.50 |
| 52 Week High | $4.21 | $10.70 |
| Indicator | CTNT | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 39.18 |
| Support Level | $1.47 | $3.81 |
| Resistance Level | $1.95 | $4.84 |
| Average True Range (ATR) | 0.16 | 0.25 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 70.91 | 10.00 |
Cheetah Net Supply Chain Service Inc is a provider of logistics and warehousing services, historically in connection with the sale of parallel-import vehicles sourced in the U.S. to be sold in the PRC market, and more recently for the transportation of other goods between the U.S. and the PRC. Parallel-import vehicles in the PRC refer to automobiles purchased directly from overseas markets and imported for sale outside of the brand manufacturer's official distribution networks. The company operates as single report segment. The company operates in the USA and overseas.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.